Will Exelixis Stock See Even Lower Levels After Negative Data From A Clinical Trial?

The stock price of Exelixis, a genomics-based pharmaceuticals company focused on oncology treatments, has seen a large 21% drop over the last five trading days, after the company announced a negative outcome from its clinical trials for Cabometyx in previously untreated liver cancer patients...